Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1 Completed

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1 Completed

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1 Terminated

24 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Phase 1 Completed

98 enrolled

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1 Terminated

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Phase 1 Completed

49 enrolled

BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT02121990 2020-08-21

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 1 Completed

17 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase 1 Completed

77 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT02418624 2019-01-16

REVIVAL

Phase 1 Completed

25 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Study of INCB123667 in Subjects With Advanced Solid Tumors

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

REVIVAL